First-in-human safety study of JMT202 in healthy volunteers
This study tests a new medicine called JMT202 for the first time in humans. It aims to see how safe the drug is and how the body processes it, in healthy volunteers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- Your body mass index (BMI) is between 18.0 and 26.0.
- You are in generally good health with no serious medical conditions (like heart, liver, kidney, or pancreas disease, or cancer).
- You have not taken any prescription or over-the-counter drugs (including herbal supplements) in the last 2 weeks.
- You do not have diabetes or a thyroid condition.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new medicine called JMT206 in healthy people to see if it is safe and how the body handles it. Healthy volunteers, ages 18 to 60, are needed to help researchers learn about the drug's effects and how it moves through the body.
This trial tests a new injectable drug, JMT202, for people with high triglycerides (a type of fat in the blood). The goal is to see if it safely lowers triglycerides and may reduce heart risk.
This trial tests a new medicine called MT-201 to see if it is safe and how the body handles it. It is for healthy volunteers aged 19 to 55 who are willing to follow study rules.
This early-stage study tests whether a new oral drug (JMKX003801) is safe in healthy volunteers. It helps find the right dose and checks for side effects.
This study tests whether a single dose of the drug JMKX001899 affects the heart's electrical activity (QTc interval) in healthy adults. It helps researchers understand the drug's safety before moving to larger studies.
This trial is testing a new medicine called JMT106 for people with advanced solid tumors (cancers that have spread or can't be removed). It's for patients whose cancer has not responded to or can't use other treatments, and who have not had a therapy targeting a specific protein (GPC3) before.
Hear when a new Healthy Subjects trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.